Objective Assessment of Outcomes Following Immediate Lymphatic Reconstruction / LYMPHA
University of Chicago · NCT06650592
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Any age listed · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 90
- US sites recruiting
- 1
- Study start
- November 26, 2024
- Record last updated
- February 2, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Immediate lymphatic reconstruction (ILR) is a novel surgical approach performed at the time of initial lymph node dissection with the goal of preventing lymphedema. It involves the identification of lymphatic channels that are transected after lymph node dissection and microsurgical anastomosis of one or more lymphatic channel with a local recipient vein to re-direct upper extremity lymphatic drainage. Although ILR carries significant promise in prevention of lymphedema, there is a lack of high-level evidence supporting its efficacy because it is a novel surgical technique that is only offered at a few centers and not routinely covered by insurance carriers yet. The University of Chicago Comprehensive Cancer Center (UCCCC) is one of the busiest microsurgery centers performing this procedure, and, as a Lymphedema Center of Excellence, is in a unique position to investigate the efficacy of ILR in preventing lymphedema. In addition, the University has access to a world class microbiome research facility and colleagues. There is no information on the skin microbiome of the axilla in patients undergoing treatment for breast cancer or those at risk for developing lymphedema. Further exploratory studies such as this in a diverse patient population may lead to practice changing research in our approach to lymphedema management and prevention. The purpose of this study is to determine the role of immediate lymphatic reconstruction and obtain objective data to correlate the existing, self-reported rates of lymphedema at the University of Chicago.
Being studied: All patients who were candidates for immediate lymphatic reconstruction (ILR)
Conditions: Lymphatic Reconstruction
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- All patients who were candidates for Immediate Lymphatic Reconstruction (ILR)
Exclusion Criteria
- None
Recruiting US locations
The University o Chicago
Chicago, IL 60637
Site contact: Leila Yazdanbakhsh · 773-834-5087 · leila.yazdanbakhsh@bsd.uchicago.edu
Study contacts (from the official record)
- Summer Hanson, MD, PhD, FACS · (773) 702-6302 · sehanson@bsd.uchicago.edu
- Leila Yazdanbakhsh · 773-834-5087 · leila.yazdanbakhsh@bsd.uchicago.edu
Similar studies in Illinois
All healthy volunteers studies in Illinois →- RecruitingHealthy volunteers
J-RISE: Relevant Implementation Strategies to Eliminate the Social and Structural Barriers to HIV Services Among Justice-involved Black Men Who Have Sex With Men and Other Key Populations
University of Chicago
- Location
- Chicago, IL
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Melrose Park, IL + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants
AbbVie
- Location
- Grayslake, IL + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers
AbbVie
- Location
- Grayslake, IL
- Eligibility basics
- Ages 18–65